Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype is a research paper published in Annals of Clinical and Translational Neurology (2021). On theSindex it has a DataRank of 0.567. It has been cited 14 times, with 9 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.406
From this paper's citation signal
Citation Network Contribution
0.161
From 8 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 9 citers.
National Institutes of Health
Grant: 5U01NS077352-11
Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) - DCC
National Institutes of Health
Grant: 5U01NS082329-02
Ibudilast Phase II trial in progressive MS
National Institutes of Health
Grant: 3U01NS077179-12S1
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
Fields of Study
Keywords